Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pikasol is a concentrated omega-3 fatty acid supplement containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). It was investigated by Oslo University Hospital in the OMEMI (Omega-3 in Elderly with Myocardial Infarction) trial to determine its effects on cardiovascular morbidity and mortality in elderly patients (aged 70-82) who recently experienced an acute myocardial infarction. The trial tested a daily dose of 1.8 g of EPA and DHA. Omega-3 fatty acids are thought to provide cardiovascular benefits through anti-inflammatory, anti-arrhythmic, and lipid-lowering mechanisms, although the OMEMI trial specifically found no significant reduction in major cardiovascular events in this elderly population compared to a corn oil placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pikasol.